Acme United Earnings Call: Record Results, Cautious Optimism

Acme United Corporation. ((ACU)) has held its Q4 earnings call. Read on for the main highlights of the call.

Acme United’s latest earnings call struck a cautiously upbeat tone, with management emphasizing record sales and profits, strong cash generation, and expanding first aid and medical capabilities. While headline growth remained modest and U.S. demand was soft, executives stressed that disciplined execution and strategic investments leave the company better positioned than its recent results suggest.

Record Sales and Earnings Amid Sluggish Growth

Acme reported 2025 net sales of $196.5 million, up 1% from 2024, and net income of $10.2 million, a 2% increase that pushed diluted EPS to $2.49. Fourth-quarter momentum was stronger, with sales rising 3% to $47.5 million and net income climbing 10% to $1.9 million, translating into a 12% jump in diluted EPS to $0.46.

Robust Cash Generation and Lower Leverage

The company generated roughly $13 million in free cash flow over 12 months, excluding the $6 million Tennessee facility purchase, underscoring solid cash conversion. Net bank debt less cash fell to $18.5 million at year-end from $21.5 million, while interest expense declined to $1.6 million, reflecting both lower borrowings and more favorable rates.

Margin Stability and Tight Cost Control

Full-year gross margin held essentially flat at 39.4%, edging up from 39.3% despite tariff disruptions and retail volatility. In Q4, gross margin dipped to 38.2%, yet tighter SG&A management reduced operating expenses to 32% of sales and helped drive a 27% year-over-year increase in operating profit for the quarter.

International and First Aid Segments Drive Growth

Europe delivered standout performance with net sales up 22% in local currency for the quarter and 4% for the year, aided by the acquisition of a cutting and sharpening tools business. Canada continued to shine as well, with net sales rising 14% in the quarter and 16% for the year, fueled by robust demand for first aid products and strong first aid and medical sales across North America.

Strategic Deals and Capacity Expansion

Management leaned into M&A and physical expansion, acquiring My Medic in early 2026, a roughly $19 million revenue brand focused on first aid, for about $18.7 million including contingent elements. The company also bought a German cutting and sharpening operation and a 78,000 square foot Tennessee facility to scale Spill Magic and blood-borne pathogen kit production, while boosting Med-Nap capacity and microbiology capabilities.

Innovation in Products, Automation and Data

Acme highlighted a patented automatic replenishment system for industrial first aid refills, which it claims can cut customer costs by 30% to over 50% versus traditional van-based servicing. The company is also broadening nonstick and ceramic cutting lines, rolling out robotics at three U.S. sites, and deploying inventory optimization tools plus nightly drone-based inventory checks at its Rocky Mount, N.C. facility.

Sourcing Flexibility and Supply Chain Response

When tariffs on certain China-sourced products fell from 145% to 30%, Acme swiftly re-routed more than 50 containers to capture cost savings and fulfill demand. Alongside rapid tactical moves, the company continued diversifying manufacturing into Vietnam, Thailand, Malaysia, India and Egypt, while renegotiating supplier pricing and freight as it worked to defend margins.

Muted Top-Line Expansion and U.S. Softness

Despite setting new records, Acme’s 1% full-year revenue growth underscored subdued organic expansion in its core business. U.S. net sales were flat in the fourth quarter and slipped 1% for the year, exposing softness in mature categories even as first aid and medical lines performed well within the domestic portfolio.

Tariffs and Order Cancellations Pressure Retail

High tariffs announced in April 2025 led many retail customers to shelve back-to-school and office promotions, materially weighing on related product sales. Management noted that some partners chose to avoid stocking rather than risk importing inventory at potential losses, amplifying short-term revenue volatility in already challenged school and office channels.

Late-Year Margin Pressure

While full-year profitability remained stable, the modest drop in Q4 gross margin from 38.7% to 38.2% signaled rising pressure late in the year. Management positioned the decline as manageable, stressing that disciplined SG&A control and pricing, combined with supply chain actions, helped offset much of the headwind.

Concentrated Weakness in School and Office

The company’s school and office segment was a clear soft spot in 2025, as tariff uncertainty and canceled orders reduced volumes and undercut U.S. growth. This concentrated weakness contrasted with stronger showings in first aid and medical categories, effectively masking underlying strength in more strategic parts of the portfolio.

Deal Valuations and Integration Challenges

The My Medic acquisition brings a growing, branded first aid business but at a relatively rich implied valuation, with EBITDA margins estimated at 5%–8% and a purchase multiple in the mid-to-high teens. Management acknowledged integration must be handled carefully, especially given earn-out and holdback structures that reflect both opportunity and potential contingent liabilities.

Macro Headwinds and Ongoing Supply Chain Risk

Executives reiterated that high inflation, elevated interest rates and the potential for new tariffs or logistics disruptions remain key external risks. Although Acme has diversified sourcing and invested in domestic production, management cautioned that shifts in macro conditions or trade policies could still adversely impact future performance.

Guidance: Leaning on First Aid Growth and Capacity

Looking ahead to 2026, Acme guided to growth led by its first aid and medical segments and a normalization of retail merchandising and promotions after a turbulent 2025. The company expects to deliver solid results in the first quarter and beyond as it leverages expanded U.S. production, broadened international sourcing and capacity from its recent acquisitions and facility investments.

Acme United’s earnings call portrayed a company balancing strong execution against a tough macro and tariff-laden backdrop, using cash generation to reduce leverage and fund strategic moves. For investors, the story is one of steady if unspectacular top-line growth but improving quality of earnings, with first aid and medical expansion and operational innovation at the core of the long-term thesis.